Portable Low-Volume Therapy for Severe Blood Loss
Abstract
In this Year 4 report we integrate our major results to date to show the overall advances that we have made in the optimization of a small volume therapy that increases survivability of lethal hemorrhagic shock in rats. This includes our results using a small-volume (1 ml/kg) resuscitation fluid based on hibernation physiology that has three main components: 4 M D-stereoisomer of beta-hydroxybutyrate (BHB), 43 mM melatonin, and 20 percent DMSO. Ten-day mean survival showed a dose-dependent trend: rats survived longer with higher concentration of infused BHB (4 M BHB, 7.38 plus or minus 1.75 days; 2 M BHB, 5.25 plus or minus 2.22 days; 0.4 M BHB, 2.07 plus or minus 2.05 days). Administering 4 M BHB without melatonin resulted in low mean survival times (4.38 plus or minus 1.42 days). All treatments containing both 4 M BHB and melatonin, regardless of melatonin concentration, resulted in mean survival times of similar to 7.5 days. Conclusions: There is a dose-dependent trend in which higher BHB concentration resulted in higher percent survival over 10 days. Melatonin provides therapeutic effects at very low concentrations evident by survival when administering a solution containing 10(exp 6)-fold lower melatonin than previously published. Melatonin is essential for survival since 4 M BHB without melatonin had a considerably reduced survival rate.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2015
- Accession Number
- AD1007997
Entities
People
- Cecilia E. Perez De Lara Rodriguez
- Lester R Drewes
- Matthew T Andrews
Organizations
- University of Minnesota